In a note published on July 14, 2022, the European Medicines Agency (EMA) states that Novavax’s Covid-19 vaccine could cause severe allergic reactions.
The Nuvaxovid vaccine from the American company Novovax uses a more traditional technique than messenger RNA: that of recombinant protein. Technique also used for several decades in certain vaccines against hepatitis B, whooping cough or influenza.
But in the face of side effects noticed recently, the European Medicines Agency indicates that it will soon “update the information on this product. This vaccine is however very little used: 250,000 doses have been administered in Europe since its launch in December 2021 according to the European Center for Disease Prevention and Control.
In France, this vaccine has been authorized since January 2022. The Nuvaxovid vaccination rate is very low: 0.1% in Martinique, Guadeloupe, Guyana and Reunion and 0% in France according to Health Insurance data.
Anaphylaxis: an immediate reaction
Some people, following this vaccine, have complained of allergic reactions severe. In an article published by INSERM in November 2017, anaphylaxis “represents the most spectacular and dangerous form of allergy: the outcome can be fatal. »
There are different clinical manifestations:
- Urticaria: rash characterized by the presence of red or pinkish plaques (or papules), superficial, rounded, well defined and in relief;
- Breathing difficulties or asthma attack;
- Digestive signs: abdominal pain, nausea, vomiting, diarrhea;
- Malaise: pallor, feeling of imminent death, drop in blood pressure, loss of consciousness or even coma.
Symptoms appear within minutes of coming into contact with the allergen. Anaphylaxis is due to inappropriate activation of cells of the immune system causing very rapid massive release histaminethe molecule causing the symptoms.
On its website, the EMA recommends that “people who develop a strong allergic reaction after receiving the first dose of Nuvaxovid should not receive the second. »